Syntopix Group plc (AIM: SYN), the speciality pharmaceutical research and
development company focused on dermatological diseases, is pleased to announce
that it has signed a 12-month exclusive evaluation agreement with a major
consumer healthcare company. In this agreement, Syntopix will make available the
Company's library of compounds for assessment of the compounds' application in
oral healthcare.
